[go: up one dir, main page]

ME02942B - Kruta disperzija dobivena ekstruzijom u rastaljenom stanju koja sadržava agens za induciranje apoptoze - Google Patents

Kruta disperzija dobivena ekstruzijom u rastaljenom stanju koja sadržava agens za induciranje apoptoze

Info

Publication number
ME02942B
ME02942B MEP-2017-299A MEP29917A ME02942B ME 02942 B ME02942 B ME 02942B ME P29917 A MEP29917 A ME P29917A ME 02942 B ME02942 B ME 02942B
Authority
ME
Montenegro
Prior art keywords
pharmaceutically acceptable
cancer
endif
supportlinebreaknewline
eqn
Prior art date
Application number
MEP-2017-299A
Other languages
English (en)
French (fr)
Inventor
Esther RÖSCH
David J Lindley
Yeshwant D Sanzgiri
Ping Tong
Peter Hoelig
Original Assignee
Abbvie Ireland Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44903438&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME02942(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Ireland Unlimited Co filed Critical Abbvie Ireland Unlimited Co
Publication of ME02942B publication Critical patent/ME02942B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (37)

1. Kruta disperzija, naznačena time, da sadržava, uglavnom u nekristalnom obliku, tako da se analizom rentgenske difrakcije ne opaža više od oko 5 % kristalnosti, spoj formule I<!--[if gte vml 1]><v:shapetype id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f"> <v:stroke joinstyle="miter"/> <v:formulas> <v:f eqn="if lineDrawn pixelLineWidth 0"/> <v:f eqn="sum @0 1 0"/> <v:f eqn="sum 0 0 @1"/> <v:f eqn="prod @2 1 2"/> <v:f eqn="prod @3 21600 pixelWidth"/> <v:f eqn="prod @3 21600 pixelHeight"/> <v:f eqn="sum @0 0 1"/> <v:f eqn="prod @6 1 2"/> <v:f eqn="prod @7 21600 pixelWidth"/> <v:f eqn="sum @8 21600 0"/> <v:f eqn="prod @7 21600 pixelHeight"/> <v:f eqn="sum @10 21600 0"/> </v:formulas> <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/> <o:lock v:ext="edit" aspectratio="t"/></v:shapetype><v:shape id="_x0000_i1025" type="#_x0000_t75" style='width:202.5pt; height:116.25pt'> <v:imagedata src="file:///C:\Users\NATASA~1.VUK\AppData\Local\Temp\msohtmlclip1\01\clip_image001.emz" o:title=""/></v:shape><![endif]--><!--[if !vml]--><!--[endif]-->pri čemu:R0 je klor;R1 i R2 su H;R3 i R4 su metil;A1 je N i A2 je CH;R5 je nitro;X je -NH-;Y je -(CH2)n- pri čemu je n = 1; iR6 je odabran iz skupine koju čine tetrahidropiranil i 4-hidroksi-4-metilcikloheksil;ilinjegove farmaceutski prihvatljive soli; pri čemu je spoj Formule I ili njegovafarmaceutski prihvatljiva sol dispergiran u krutoj matrici koja sadržava (a)najmanje jedan farmaceutski prihvatljiv polimerni nosač topljiv u vodi i (b)barem jedan farmaceutski prihvatljiv surfaktant; pri čemu je spoj ili njegovafarmaceutski prihvatljiva sol prisutan u ekvivalentnoj količini od oko 5 % dooko 15 % težinskog udjela, barem jedan farmaceutski prihvatljiv polimerni nosačtopljiv u vodi prisutan je u količini od oko 70 % do oko 85 % težinskog udjelai najmanje jedan farmaceutski prihvatljiv surfaktant, koji je prisutan ukoličini od oko 5 % do oko 15 % težinskog udjela.
2. Čvrsta disperzija u skladu s patentnim zahtjevom 1, naznačena time, da je spoj Formule I 4-(4-{[2-(4-klorfenil)-4,4-dimetilcikloheks-1-en-1-il]metil}piperazin-1-il)-N-({3-nitro-4-[(tetrahidro-2H-piran-4-ilmetil)amino]fenil}sulfonil)-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid ili njegova farmaceutski prihvatljiva sol.
3. Čvrsta disperzija u skladu s patentnim zahtjevom 1, naznačena time, da je spoj Formule I 4-(4-{[2-(4-klorfenil)-4,4-dimetilcikloheks-1-en-1-il]metil}piperazin-1-il)-N-[(4-{[(trans-4-hidroksi-4-metilcikloheksil)metil]amino}-3-nitrofenil)sulfonil]-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid ili njegova farmaceutski prihvatljiva sol. <!--[if !supportLineBreakNewLine]--> <!--[endif]-->
4. Čvrsta disperzija u skladu s patentnim zahtjevom 1, naznačena time, da je spoj Formule I 4-(4-{[2-(4-klorfenil)-4,4-dimetilcikloheks-1-en-1-il]metil}piperazin-il)-N-[(4-{[(cis-4-hidroksi-4-metilcikloheksil)metil]amino}-3-nitrofenil)sulfonil]-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid ili njegova farmaceutski prihvatljiva sol. <!--[if !supportLineBreakNewLine]--> <!--[endif]-->
5. Čvrsta disperzija u skladu s patentnim zahtjevom 1, naznačena time, da je najmanje jedan farmaceutski prihvatljiv polimerni nosač topljiv u vodi kopovidon.
6. Čvrsta disperzija u skladu s patentnim zahtjevom 5, naznačena time, da je najmanje jedan farmaceutski prihvatljiv surfaktant polisorbat. <!--[if !supportLineBreakNewLine]--> <!--[endif]-->
7. Čvrsta disperzija u skladu s patentnim zahtjevom 6, naznačena time, da nadalje sadržava najmanje jedan lubrikant. <!--[if !supportLineBreakNewLine]--> <!--[endif]-->
8. Čvrsta disperzija u skladu s patentnim zahtjevom 7, naznačena time, da najmanje jedan lubrikant sadržava koloidni silicijev dioksid. <!--[if !supportLineBreakNewLine]--> <!--[endif]-->
9. Postupak za pripravu krute disperzije, naznačen time, da obuhvaća: (a) podvrgavanje povišenoj temperaturi (i) aktivnog farmaceutskog sastojka (API) koji je spoj Formule Ipri čemu: R0 je klor; R1 i R2 su H; R3 i R4 su metil; A1 je N i A2 je CH; R5 je nitro; X je -NH-; Y je -(CH2)n- pri čemu je n 1; i R6 je odabran iz skupine koju čine tetrahidropiranil i 4-hidroksi-4-metilcikloheksil; ili njegove farmaceutski prihvatljive soli, (ii) farmaceutski prihvatljiv polimerni nosač koji je topljiv u vodi i (iii) farmaceutski prihvatljiv surfaktant, čime se dobiva polukrutina koja se može obrađivati ekstruzijom; (b) ekstruziju polukrute smjese; i (c) hlađenje dobivenog ekstrudata radi dobivanja čvrste matrice koja sadržava farmaceutski prihvatljiv polimerni nosač topljiv u vodi i farmaceutski prihvatljiv surfaktant, u kojem su spoj Formule I ili njegova farmaceutski prihvatljivu sol dispergirani u njegovom uglavnom nekristalnom obliku, tako da se analizom rentgenske difrakcije ne opaža više od oko 5 % kristalnosti.
10. Postupak u skladu s patentnim zahtjevom 9, naznačen time, da nadalje obuhvaća korak miješanja API-ja, farmaceutski prihvatljivog polimernog nosača topljivog u vodi i farmaceutski prihvatljivog surfaktanta prije navedenog koraka podvrgavanja povišenoj temperaturi; ili nadalje obuhvaća korak miješanja API-ja, farmaceutski prihvatljivog polimernog nosača topljivog u vodi i farmaceutski prihvatljivog surfaktanta tijekom navedenog koraka podvrgavanja povišenoj temperaturi. <!--[if !supportLineBreakNewLine]--> <!--[endif]-->
11. Postupak u skladu s patentnim zahtjevom 9, naznačen time, da je navedena povišena temperatura od oko 70 °C do oko 250 °C ili od oko 90 °C do oko 160 °C. <!--[if !supportLineBreakNewLine]--> <!--[endif]-->
12. Postupak u skladu s patentnim zahtjevom 9, naznačen time, da nadalje sadržava korak kalendriranja ekstrudata prije ili tijekom navedenog koraka hlađenja.
13. Postupak u skladu s patentnim zahtjevom 12, naznačen time, da se korak kalendriranja ekstrudata provodi prije navedenog koraka hlađenja.
14. Postupak u skladu s patentnim zahtjevom 13, naznačen time, da je API 4-(4-{[2-(4-klorfenil)-4,4-dimetilcikloheks-1-en-1-il]metil}piperazin-1-il)-N-({3-nitro-4-[(tetrahidro-2H-piran-4-ilmetil)amino]fenil}sulfonil)-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid ili njegova farmaceutski prihvatljive soli. <!--[if !supportLineBreakNewLine]--> <!--[endif]-->
15. Postupak u skladu s patentnim zahtjevom 9, naznačen time, da je API 4-(4-{[2-(4-klorfenil)-4,4-dimetilcikloheks-1-en-1-il]metil}piperazin-1-il)-N-[(4-{[(trans-4-hidroksi-4-metilcikloheksil)metil]amino }-3-nitrofenil)sulfonil]-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid ili njegova farmaceutski prihvatljiva sol. <!--[if !supportLineBreakNewLine]--> <!--[endif]-->
16. Postupak u skladu s patentnim zahtjevom 9, naznačen time, da je API 4-(4-{[2-(4-klorfenil)-4,4-dimetilcikloheks-1-en-1-il] metil}piperazin-1-il)-N-[(4-{[(cis-4-hidroksi-4-metilcicloheksil)metil]amino}-3-nitrofenil)sulfonil]-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid ili njegova farmaceutski prihvatljiva sol. <!--[if !supportLineBreakNewLine]--> <!--[endif]-->
17. Postupak u skladu s patentnim zahtjevom 14, naznačen time, da je farmaceutski prihvatljiv polimerni nosač topljiv u vodi kopovidon. <!--[if !supportLineBreakNewLine]--> <!--[endif]-->
18. Postupak u skladu s patentnim zahtjevom 14, naznačen time, da je farmaceutski prihvatljiv surfaktant polisorbat. <!--[if !supportLineBreakNewLine]--> <!--[endif]-->
19. Farmaceutski oblik doziranja za oralnu primjenu, naznačen time, da sadržava krutu disperziju koja sadržava uglavnom nekristalni oblik, tako da se analizom rentgenske difrakcije ne opaža više od oko 5 % kristalnosti, spoj Formule I <!--[if gte vml 1]><v:shapetype id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f"> <v:stroke joinstyle="miter"/> <v:formulas> <v:f eqn="if lineDrawn pixelLineWidth 0"/> <v:f eqn="sum @0 1 0"/> <v:f eqn="sum 0 0 @1"/> <v:f eqn="prod @2 1 2"/> <v:f eqn="prod @3 21600 pixelWidth"/> <v:f eqn="prod @3 21600 pixelHeight"/> <v:f eqn="sum @0 0 1"/> <v:f eqn="prod @6 1 2"/> <v:f eqn="prod @7 21600 pixelWidth"/> <v:f eqn="sum @8 21600 0"/> <v:f eqn="prod @7 21600 pixelHeight"/> <v:f eqn="sum @10 21600 0"/> </v:formulas> <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/> <o:lock v:ext="edit" aspectratio="t"/> </v:shapetype><v:shape id="_x0000_i1025" type="#_x0000_t75" style='width:175.5pt; height:101.25pt'> <v:imagedata src="file:///C:\Users\NATASA~1.VUK\AppData\Local\Temp\msohtmlclip1\01\clip_image001.emz" o:title=""/> </v:shape><![endif]--><!--[if !vml]--><!--[endif]--> pri čemu: R0 je klor; R1 i R2 su H; R3 i R4 su metil; A1 je N i A2 je CH; R5 je nitro; X je -NH-; Y je -(CH2)n- pri čemu je n 1; i R6 je odabran iz skupine koju čine tetrahidropiranil i 4-hidroksi-4-metilcikloheksil ili njegove farmaceutski prihvatljive soli; dispergiran u krutoj matrici koja sadržava (a) najmanje jedan farmaceutski prihvatljiv polimerni nosač topljiv u vodi i (b) najmanje jedan farmaceutski prihvatljiv surfaktant; pri čemu je spoj ili njegova farmaceutski prihvatljiva sol prisutan u ekvivalentnoj količini od oko 5 % do oko 15 % težinskog udjela, barem jedan farmaceutski prihvatljiv polimerni nosač topljiv u vodi je prisutan u količini od oko 70 % do oko 85 % težinskog udjela i najmanje jedan farmaceutski prihvatljiv surfaktant prisutan u količini od oko 5 % do oko 15 % težinskog udjela.
20. Farmaceutski oblik doziranja za oralnu primjenu u skladu s patentnim zahtjevom 19, naznačen time, da kruti disperzijski pripravak sadržava 4-(4-{[2-(4-klorfenil)-4,4-dimetilcikloheks-1-en-1-il]metil}piperazin-1-il)-N-({3-nitro-4-[(tetrahidro-2H-piran-4-ilmetil)amino]fenil}sulfonil)-2-(1H-pirolo[2,3-b]piridin-5- iloksi)benzamid ili njegovu farmaceutski prihvatljivu sol. <!--[if !supportLineBreakNewLine]--> <!--[endif]-->
21. Farmaceutski oblik doziranja za oralnu primjenu u skladu s patentnim zahtjevom 19, naznačen time, da kruti disperzijski pripravak sadržava 4-(4-{[2-(4-klorfenil)-4,4-dimetilcikloheks-1-en-1-il]metil}piperazin-1-il)-N-[(4-{[(trans-4-hidroksi-4-metilcikloheksil)metil]amino}-3- nitrofenil)sulfonil]-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid ili njegovu farmaceutski prihvatljivu sol. <!--[if !supportLineBreakNewLine]--> <!--[endif]-->
22. Farmaceutski oblik doziranja za oralnu primjenu u skladu s patentnim zahtjevom 19, naznačen time, da kruti disperzijski pripravak sadržava 4-(4-{[2-(4-klorfenil)-4,4-dimetilcikloheks-1-en-1-il]metil}piperazin-1-il)-N-[(4-[(cis-4-hidroksi-4-metilcikloheksil)metil]amino}-3-nitrofenil)sulfonil]-2-(1H-pirolo[2,3- b]piridin-5-iloksi)benzamid ili njegovu farmaceutski prihvatljivu sol. <!--[if !supportLineBreakNewLine]--> <!--[endif]-->
23. Farmaceutski oblik doziranja za oralnu primjenu u skladu s patentnim zahtjevom 19, naznačen time, da je barem jedan farmaceutski prihvatljiv polimerni nosač kopovidon, a barem jedan surfaktant polisorbat. <!--[if !supportLineBreakNewLine]--> <!--[endif]-->
24. Farmaceutski oblik doziranja za oralnu primjenu u skladu s patentnim zahtjevom 19, naznačen time, da je oblik doziranja kapsula. <!--[if !supportLineBreakNewLine]--> <!--[endif]-->
25. Farmaceutski oblik doziranja za oralnu primjenu u skladu s patentnim zahtjevom 19, naznačen time, da je oblik za doziranje tableta.
26. Farmaceutski oblik doziranja za oralnu primjenu u skladu s patentnim zahtjevom 19, naznačen time, da je jedinična doza spoja Formule I između 10 mg i 1000 mg. <!--[if !supportLineBreakNewLine]--> <!--[endif]-->
27. Kruta disperzija u skladu s patentnim zahtjevom 1, naznačena time, da se koristi kao lijek
28. Kruta disperzija u skladu s patentnim zahtjevom 27, naznačena time, da se koristi za liječenje neoplastične, imune ili autoimune bolesti. <!--[if !supportLineBreakNewLine]--> <!--[endif]-->
29. Kruta disperzija za uporabu u skladu s patentnim zahtjevom 28, naznačena time, da se koristi za liječenje neoplastične bolesti izabrane iz skupine koju čine rak, mezoteliom, rak mokraćnog mjehura, rak gušterače, rak kože, rak glave ili vrata, kožni ili intraokularni melanom, rak jajnika, rak dojke, rak maternice, karcinom jajovoda, karcinom endometrija, karcinom cerviksa, karcinom vagine, karcinom vulve, rak kostiju, rak debelog crijeva, rak rektuma, rak analnog područja, rak želuca, gastrointestinalni rak (želuca, kolorektalni i / ili duodenalni), kronična limfocitna leukemija, akutna limfocitna leukemija, rak jednjaka, rak tankog crijeva, rak endokrinog sustava, rak štitne žlijezde, rak paratiroidnih žlijezda, rak nadbubrežne žlijezde, sarkoma mekog tkiva, rak uretre, rak penisa, rak testisa, hepatocelularni rak (hepatičnog i / ili žučnog kanala), primarni ili sekundarni tumor središnjeg živčanog sustava, primarni ili sekundarni tumor mozga, Hodgkinova bolest, kronična ili akutna leukemija, kronična mijeloidna leukemija, limfocitni limfom, limfoblastična leukemija, folikularni limfom, limfoidni malignitet uzrokovan T-stanicama ili B-stanicama, melanom, multipli mijelom, oralni karcinom, rak ne-malih stanica pluća, rak prostate, rak malih stanica pluća, karcinom bubrega i / ili uretera, karcinom bubrežnih stanica, karcinom bubrežne zdjelice, neoplazam središnjeg živčanog sustava, primarni limfom središnjeg živčanog sustava, ne-Hodgkinov limfom, tumor kralježnice, gliom moždanog debla, adenom hipofize, adrenokortikalni rak, rak žučnog mjehura, raka slezene, kolangiokarcinom, fibrosarkom, neuroblastom, retinoblastom i njihovih kombinacija. <!--[if !supportLineBreakNewLine]--> <!--[endif]-->
30. Kruta disperzija za uporabu u skladu s patentnim zahtjevom 29, naznačena time, da je neoplastična bolest ne-Hodgkinov limfom. <!--[if !supportLineBreakNewLine]--> <!--[endif]-->
31. Kruta disperzija za uporabu u skladu s patentnim zahtjevom 29, naznačena time, da je neoplastična bolest kronična limfocitna leukemija ili akutna limfocitna leukemija. <!--[if !supportLineBreakNewLine]--> <!--[endif]-->
32. Kruta disperzija u skladu s patentnim zahtjevom 28, naznačena time, da se koristi za liječenje imune ili autoimune bolesti. <!--[if !supportLineBreakNewLine]--> <!--[endif]-->
33. Kruta disperzija za uporabu u skladu s patentnim zahtjevom 28, naznačena time, da je kruta disperzija namijenjena za davanje u ekvivalentnoj dozi matičnog spoja od oko 50 do oko 500 mg na dan spoja Formule I ili njegove farmaceutski prihvatljive soli pri prosječnom trajanju tretmana od oko 3 sata do oko 7 dana; ili pri čemu je kruta disperzija namijenjena za davanje u ekvivalentnoj dozi matičnog spoja od oko 50 do oko 500 mg na dan spoja Formule I ili njegove farmaceutski prihvatljive soli. <!--[if !supportLineBreakNewLine]--> <!--[endif]-->
34. Kruta disperzija u skladu s patentnim zahtjevom 2, naznačena time, da nadalje sadržava: između 0,1 % i 2 % težinskih udjela koloidnog silicijevog dioksida.
35. Kruta disperzija u skladu s patentnim zahtjevom 34, naznačena time, da sadržava: između 5 % i 12 % težinskih udjela 4-(4-{[2-(4-klorfenil)-4,4-dimetilcikloheks-1-en-1-il]metil}piperazin-1-il)-N-({3-nitro-4-[(tetrahidro-2H-piran-4-ilmetil)amino]fenil}sulfonil)-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid ili njegovu farmaceutski prihvatljivu sol u količini koja je ekvivalentna matičnom spoju. <!--[if !supportLineBreakNewLine]--> <!--[endif]--> <!--[if !supportLineBreakNewLine]--> <!--[endif]-->
36. Kruta disperzija u skladu s patentnim zahtjevom 35, naznačena time, da je polimerni nosač kopovidon, surfaktant je polisorbat, a lubrikant je koloidni silicijev dioksid.
37. Kruta disperzija u skladu s patentnim zahtjevom 35, naznačena time, da sadržava: 12 težinskih udjela aktivnog farmaceutskog sastojka (API) koji sadržava 4-(4-{[2-(4-klorfenil)-4,4-dimetilcikloheks-1-en-1-il]metil}piperazin-1-il)-N-({3-nitro-4-[(tetrahidro-2H-piran-4-ilmetil)amino]fenil}sulfonil)-2-(1H-pirolo[2,3-b]piridin-5-iloksi)benzamid ili njegovu farmaceutski prihvatljivu sol u količini koja je ekvivalentna matičnom spoju; 80 težinskih udjela kopovidona 60/40; 7 težinskih udjela polisorbata 80; i 1 težinski udio koloidnog silicijevog dioksida.
MEP-2017-299A 2010-10-29 2011-10-05 Kruta disperzija dobivena ekstruzijom u rastaljenom stanju koja sadržava agens za induciranje apoptoze ME02942B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40852710P 2010-10-29 2010-10-29
EP11770975.8A EP2613769B1 (en) 2010-10-29 2011-10-05 Melt-extruded solid dispersions containing an apoptosis-inducing agent
PCT/US2011/054959 WO2012121758A1 (en) 2010-10-29 2011-10-05 Melt-extruded solid dispersions containing an apoptosis-inducing agent

Publications (1)

Publication Number Publication Date
ME02942B true ME02942B (me) 2018-04-20

Family

ID=44903438

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2017-299A ME02942B (me) 2010-10-29 2011-10-05 Kruta disperzija dobivena ekstruzijom u rastaljenom stanju koja sadržava agens za induciranje apoptoze

Country Status (41)

Country Link
US (2) US20120108590A1 (me)
EP (3) EP3219308A1 (me)
JP (2) JP5902187B2 (me)
KR (2) KR101836820B1 (me)
CN (2) CN108175749B (me)
AR (2) AR083656A1 (me)
AU (1) AU2011361704B2 (me)
BR (1) BR112013010524A8 (me)
CA (1) CA2813985C (me)
CL (1) CL2013001120A1 (me)
CO (1) CO6781472A2 (me)
CR (2) CR20180289A (me)
CY (1) CY1119993T1 (me)
DK (1) DK2613769T3 (me)
DO (2) DOP2013000092A (me)
EC (2) ECSP13012647A (me)
ES (1) ES2647583T3 (me)
GT (1) GT201300102A (me)
HK (1) HK1243761A1 (me)
HR (1) HRP20171884T1 (me)
HU (1) HUE035169T2 (me)
IL (2) IL226215A (me)
LT (1) LT2613769T (me)
ME (1) ME02942B (me)
MX (2) MX362113B (me)
MY (1) MY189224A (me)
NO (1) NO2613769T3 (me)
NZ (1) NZ608907A (me)
PE (2) PE20171242A1 (me)
PH (1) PH12013500686A1 (me)
PL (1) PL2613769T3 (me)
PT (1) PT2613769T (me)
RS (1) RS56718B1 (me)
RU (2) RU2577859C2 (me)
SG (2) SG189477A1 (me)
SI (1) SI2613769T1 (me)
TW (2) TWI535699B (me)
UA (1) UA113500C2 (me)
UY (3) UY39192A (me)
WO (1) WO2012121758A1 (me)
ZA (2) ZA201302669B (me)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9034875B2 (en) 2009-05-26 2015-05-19 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
US20220315555A1 (en) 2009-05-26 2022-10-06 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
EP2632436B1 (en) 2010-10-29 2018-08-29 Abbvie Inc. Solid dispersions containing an apoptosis-inducing agent
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
LT2643322T (lt) 2010-11-23 2018-01-10 Abbvie Inc. Apoptozę skatinančio agento druskos ir kristalinės formos
AU2011332000B2 (en) 2010-11-23 2016-07-07 Abbvie Ireland Unlimited Company Methods of treatment using selective Bcl-2 inhibitors
WO2012177927A1 (en) 2011-06-21 2012-12-27 Mayo Foundation For Medical Education And Research Transgenic animals capable of being induced to delete senescent cells
WO2013090645A1 (en) 2011-12-13 2013-06-20 Buck Institute For Research On Aging Methods for improving medical therapies
WO2013158664A2 (en) 2012-04-17 2013-10-24 Kythera Biopharmaceuticals, Inc. Use of engineered viruses to specifically kill senescent cells
US9901080B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells
US9901081B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse for determining the role of senescent cells in cancer
CN104768581A (zh) 2012-09-07 2015-07-08 吉宁特有限公司 II型抗CD20抗体与选择性Bcl-2抑制剂的组合治疗
WO2014048782A1 (en) * 2012-09-27 2014-04-03 Basf Se A storage-stable dust-free homogeneous particulate formulation comprising at least one water-soluble vitamin e-derivative and at least one hydrophilic polymer
AR095265A1 (es) 2013-03-13 2015-09-30 Abbvie Inc Procesos para la preparación de un agente inductor de la apoptosis
DK2970263T3 (en) 2013-03-13 2018-08-13 Abbvie Inc PROCESSES FOR THE MANUFACTURE OF AN APOPTOSIS-PRACTICING EFFECT
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US20170216286A1 (en) 2014-01-28 2017-08-03 Mayo Foundation For Medical Education And Research Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid
US20190269675A1 (en) 2014-01-28 2019-09-05 Buck Institute for Research and Aging Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agents
US10328058B2 (en) 2014-01-28 2019-06-25 Mayo Foundation For Medical Education And Research Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques
RU2716256C2 (ru) 2014-01-28 2020-03-11 Бак Инститьют Фо Ресеч Он Эйджинг Способы и композиции для уничтожения стареющих клеток и для лечения заболеваний и расстройств, ассоциированных со старением
US12168004B2 (en) 2014-02-05 2024-12-17 Merck Sharp & Dohme Llc Treatment of migraine
KR20220136460A (ko) * 2014-02-05 2022-10-07 머크 샤프 앤드 돔 엘엘씨 Cgrp-활성 화합물에 대한 정제 제제
US9238652B2 (en) 2014-03-04 2016-01-19 Abbvie Inc. Processes for the preparation of an apoptosis-inducing agent
HRP20211813T1 (hr) 2014-08-11 2022-03-04 Acerta Pharma B.V. Terapeutske kombinacije inhibitora btk i inhibitora bcl-2
JP6691752B2 (ja) * 2014-08-29 2020-05-13 花王株式会社 難溶解性ポリフェノール類を含有する固体分散体の製造方法
CN104586770A (zh) * 2014-12-30 2015-05-06 山东博迈康药物研究有限公司 一种盐酸帕唑帕尼的热熔挤出制剂及其制备方法
GB201502073D0 (en) * 2015-02-09 2015-03-25 Cubic Pharmaceuticals Ltd And Delta Pharmaceuticals Ltd HDEG technology
US10195213B2 (en) 2015-03-13 2019-02-05 Unity Biotechnology, Inc. Chemical entities that kill senescent cells for use in treating age-related disease
AU2016349279A1 (en) 2015-11-03 2018-05-10 Board Of Regents, The University Of Texas System Combination of Bcl-2 inhibitor and MEK inhibitor for the treatment of cancer
CN106957315B (zh) * 2016-01-08 2019-08-13 中国人民解放军第二军医大学 N-取代苯磺酰基-氮杂吲哚氧基苯甲酰胺类化合物及其制备药物的用途
EP3426655A1 (en) 2016-03-10 2019-01-16 Assia Chemical Industries Ltd. Solid state forms of venetoclax and processes for preparation of venetoclax
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
BR112018075176A2 (pt) * 2016-06-09 2019-06-04 Dr Reddys Laboratories Ltd formas sólidas de venetoclax e processos para a preparação de venetoclax
US20190225607A1 (en) * 2016-07-06 2019-07-25 Concert Pharmaceuticals, Inc. Deuterated Venetoclax
CN107648185A (zh) * 2016-07-25 2018-02-02 常州爱诺新睿医药技术有限公司 一种无定型Venetoclax与药用辅料的固体分散体及其制备方法
WO2018069941A2 (en) 2016-10-14 2018-04-19 Mylan Laboratories Limited Polymorphic forms of venetoclax
EP3333167A1 (en) * 2016-12-09 2018-06-13 LEK Pharmaceuticals d.d. Solid forms of venetoclax
WO2018127130A1 (en) * 2017-01-07 2018-07-12 Shanghai Fochon Pharmaceutical Co., Ltd. Compounds as bcl-2-selective apoptosis-inducing agents
LT3612531T (lt) 2017-04-18 2022-09-26 Shanghai Fochon Pharmaceutical Co., Ltd. Apoptozę sukeliančios medžiagos
FI3672976T3 (fi) 2017-08-23 2024-02-21 Guangzhou Lupeng Pharmaceutical Company Ltd Bcl-2-inhibiittoreita
WO2019135253A1 (en) 2018-01-02 2019-07-11 Mylan Laboratories Limited Polymorphic forms of venetoclax
US11318134B2 (en) 2018-01-10 2022-05-03 Recurium Ip Holdings, Llc Benzamide compounds
US12383545B1 (en) 2018-06-08 2025-08-12 Allergan Pharmaceuticals International Limited Treatment of migraine
US12090148B2 (en) 2020-07-29 2024-09-17 Allergan Pharmaceuticals International Limited Treatment of migraine
WO2020023435A1 (en) 2018-07-24 2020-01-30 Albany Molecular Research, Inc. Venetoclax basic salts and processes for the purification of venetoclax
US12220419B2 (en) 2018-08-22 2025-02-11 Newave Pharmaceutical Inc. BCL-2 inhibitors
WO2021053155A1 (en) 2019-09-18 2021-03-25 Aprea Therapeutics Ab Combination treatment with a p53 reactivator and an inhibitor of an antiapoptotic bcl-2 family protein
WO2021173523A1 (en) * 2020-02-24 2021-09-02 Newave Pharmaceutical Inc. Hot melt extruded solid dispersions containing a bcl2 inhibitor
JP2023551056A (ja) * 2020-11-25 2023-12-06 アセンテージ ファーマ（スーチョウ）カンパニー，リミティド 固体分散体、医薬製剤、その製造方法及び応用
CA3206184A1 (en) 2020-12-22 2022-06-30 Allergan Pharmaceuticals International Limited Treatment of migraine
US12350259B2 (en) 2021-09-27 2025-07-08 Allergan Pharmaceuticals International Limited Methods of treating migraine
EP4656186A1 (en) * 2023-03-10 2025-12-03 ST Pharm Co., Ltd. Novel solid dispersion and method for preparing same

Family Cites Families (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665379A (en) 1990-09-28 1997-09-09 Pharmacia & Upjohn Aktiebolag Lipid particle forming matrix, preparation and use thereof
MY115155A (en) 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
IL111004A (en) 1993-09-30 1998-06-15 American Home Prod Oral formulations of rapamycin
US5536729A (en) 1993-09-30 1996-07-16 American Home Products Corporation Rapamycin formulations for oral administration
ATE317397T1 (de) 1993-11-17 2006-02-15 Athena Neurosciences Inc Transparente flüssigkeit zur verabreichung von verkapselten medikamenten
US5759548A (en) 1993-11-30 1998-06-02 Lxr Biotechnology Inc. Compositions which inhibit apoptosis, methods of purifying the compositions and uses thereof
GB9405304D0 (en) 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US5538737A (en) 1994-11-30 1996-07-23 Applied Analytical Industries, Inc. Oral compositions of H2 -antagonists
BE1009856A5 (fr) 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
EP1019385B1 (en) 1995-09-15 2004-01-14 PHARMACIA &amp; UPJOHN COMPANY Aminoaryl oxazolidinone n-oxides
US6964946B1 (en) 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
CN1300173C (zh) 1996-02-09 2007-02-14 艾博特生物技术有限公司 结合人TNFα的人抗体
US5891469A (en) 1997-04-02 1999-04-06 Pharmos Corporation Solid Coprecipitates for enhanced bioavailability of lipophilic substances
US20030220234A1 (en) 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
BE1011899A6 (fr) 1998-04-30 2000-02-01 Ucb Sa Compositions pharmaceutiques gelifiables utilisables.
ID26984A (id) 1998-07-06 2001-02-22 Bristol Myers Squibb Co Senyawa-senyawa sulfonamida sebagai antagonis reseptor angiotensin endotelin ganda
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
DE19913692A1 (de) 1999-03-25 2000-09-28 Basf Ag Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
DE19929361A1 (de) 1999-06-25 2001-01-04 Basf Ag Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
US20030236236A1 (en) 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
GB9918037D0 (en) 1999-07-30 1999-09-29 Biochemie Gmbh Organic compounds
WO2001047891A1 (en) 1999-12-28 2001-07-05 Eisai Co., Ltd. Heterocyclic compounds having sulfonamide groups
US20060183776A9 (en) 2000-03-03 2006-08-17 Eisai Co., Ltd. Liquid dosage formulations of donepezil
US20020055631A1 (en) 2000-09-20 2002-05-09 Augeri David J. N-acylsulfonamide apoptosis promoters
US6720338B2 (en) 2000-09-20 2004-04-13 Abbott Laboratories N-acylsulfonamide apoptosis promoters
AR031130A1 (es) 2000-09-20 2003-09-10 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
CN1527830A (zh) 2001-01-31 2004-09-08 �Ʒ� 用作pde4同工酶的抑制剂的醚衍生物
US6927009B2 (en) 2001-05-22 2005-08-09 Fuji Photo Film Co., Ltd. Positive photosensitive composition
UA74889C2 (en) 2001-06-06 2006-02-15 Lilly Co Eli Benzoylsulfonamides and sulfonylbenzamidines for the application as antitumour agents
GB0123400D0 (en) 2001-09-28 2001-11-21 Novartis Ag Organic compounds
DK1471887T3 (da) 2002-02-04 2010-06-07 Elan Pharma Int Ltd Nanopartikelkompositioner der har lysozym som overfladestabiliseringsmiddel
PL208114B1 (pl) 2002-02-26 2011-03-31 Astrazeneca Ab Kompozycja farmaceutyczna, sposób jej wytwarzania i zastosowanie
ES2342660T3 (es) 2002-02-26 2010-07-12 Astrazeneca Ab Nuevas formas cristalinas del compuesto anticancerigeno zd1839.
FR2836914B1 (fr) 2002-03-11 2008-03-14 Aventis Pharma Sa Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
MY129850A (en) 2002-04-29 2007-05-31 Merck Sharp & Dohme Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
US20060177430A1 (en) 2002-12-20 2006-08-10 Chakshu Research Inc Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US20050048112A1 (en) 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
JP4336678B2 (ja) 2003-09-04 2009-09-30 株式会社日立超エル・エス・アイ・システムズ 半導体装置
WO2005049593A2 (en) 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US8614318B2 (en) 2003-11-13 2013-12-24 Abbvie Inc. Apoptosis promoters
US7767684B2 (en) 2003-11-13 2010-08-03 Abbott Laboratories Apoptosis promoters
US7642260B2 (en) 2003-11-13 2010-01-05 Abbott Laboratories, Inc. Apoptosis promoters
US7973161B2 (en) 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
US7790190B2 (en) 2004-03-20 2010-09-07 Yasoo Health, Inc. Aqueous emulsions of lipophile solubilized with vitamin E TPGS and linoleic acid
US7307163B2 (en) 2004-04-19 2007-12-11 Symed Labs Limited Process for the preparation of linezolid and related compounds
US7318503B2 (en) 2004-04-26 2008-01-15 Akebono Corporation (North America) Pad retaining clips
US20070237823A1 (en) 2004-05-04 2007-10-11 Thomas Bock Solid Pharmaceutical Form Comprising and Ltb4 Antagonist
DE602004020812D1 (de) 2004-07-20 2009-06-04 Symed Labs Ltd Neue zwischenprodukte für linezolid und verwandte verbindungen
MY191349A (en) 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
WO2006026501A1 (en) 2004-08-27 2006-03-09 Bayer Pharmaceuticals Corporation New pharmaceutical compositions for the treatment of cancer
FR2875409B1 (fr) 2004-09-17 2010-05-07 Sanofi Aventis Composition pharmaceutique comprenant une dispersion solide a matrice polymere comprenant une phase continue de polydextrose et une phase continue d'un polymere autre que du polydextrose
WO2006039164A2 (en) 2004-09-29 2006-04-13 Amr Technology, Inc. Novel cyclosporin analogues and their pharmaceutical uses
US8624027B2 (en) 2005-05-12 2014-01-07 Abbvie Inc. Combination therapy for treating cancer and diagnostic assays for use therein
KR101509440B1 (ko) 2005-05-12 2015-04-07 애브비 바하마스 리미티드 아폽토시스 촉진제
DE602006014540D1 (en) 2005-05-16 2010-07-08 Irm Llc Pyrrolopyridinderivate als proteinkinaseinhibitoren
CN1706371B (zh) 2005-05-27 2010-11-10 沈阳药科大学 一种高效的马蔺子素制剂及其制备方法
TW200716636A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
NZ565255A (en) 2005-06-22 2010-04-30 Plexxikon Inc Pyrrolo[2,3-b] pyridine derivatives as protein kinase inhibitors
US7514068B2 (en) 2005-09-14 2009-04-07 Concert Pharmaceuticals Inc. Biphenyl-pyrazolecarboxamide compounds
ATE544444T1 (de) 2005-10-11 2012-02-15 Yissum Res Dev Co Zusammensetzungen für die nasale abgabe
EP1959926A1 (en) 2005-10-25 2008-08-27 Abbott Laboratories Formulation comprising a drug of low water solubility and method of use thereof
US7151188B1 (en) 2005-11-16 2006-12-19 General Electric Company Process for the production of mercaptoalkylalkoxysilanes
US20080085313A1 (en) 2006-05-15 2008-04-10 Given Bruce D Methods and compositions for treatment of sleep apnea
MX2009000132A (es) 2006-06-30 2009-01-26 Schering Corp Metodo para el uso de piperidinas sustituidas que incrementan la actividad de p53.
WO2008008375A2 (en) 2006-07-14 2008-01-17 Chemocentryx, Inc. Triazolyl pyridyl benzenesulfonamides as ccr2 or ccr9 modulators for the treatment of inflammation
EP1880715A1 (en) 2006-07-19 2008-01-23 Abbott GmbH & Co. KG Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same
US7799790B2 (en) 2006-07-20 2010-09-21 Helm Ag Amorphous aripiprazole and process for the preparation thereof
RU2454220C2 (ru) 2006-08-16 2012-06-27 Новартис Аг Способ получения твердых дисперсий высококристаллических терапевтических соединений
CN101534904B (zh) 2006-09-05 2013-11-06 Abbvie公司 治疗血小板过量的bcl抑制剂
US8796267B2 (en) 2006-10-23 2014-08-05 Concert Pharmaceuticals, Inc. Oxazolidinone derivatives and methods of use
CA2667720A1 (en) 2006-11-09 2008-05-15 Abbott Gmbh & Co. Kg. Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
US20080181948A1 (en) * 2006-11-15 2008-07-31 Abbott Laboratories Solid pharmaceutical dosage formulations
WO2008064116A2 (en) 2006-11-16 2008-05-29 Abbott Laboratories Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
CN101616902B (zh) 2007-02-15 2013-03-27 弗·哈夫曼-拉罗切有限公司 作为taar1配体的2-氨基*唑啉类化合物
RU2351352C2 (ru) 2007-04-09 2009-04-10 Закрытое акционерное общество "Санкт-Петербургский институт фармации" Твердая нанокомпозиция для доставки биологически активных веществ
US8536157B2 (en) 2007-04-13 2013-09-17 The University Of Melbourne Non-steroidal compounds
BRPI0810362A2 (pt) 2007-04-19 2014-10-29 Concert Pharmaceuticals Inc Compostos de morfolinila deuterados
US7531685B2 (en) 2007-06-01 2009-05-12 Protia, Llc Deuterium-enriched oxybutynin
WO2009035598A1 (en) 2007-09-10 2009-03-19 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
US20090118238A1 (en) 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US20090088416A1 (en) 2007-09-26 2009-04-02 Protia, Llc Deuterium-enriched lapaquistat
US20090082471A1 (en) 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched fingolimod
CN101883586A (zh) 2007-10-01 2010-11-10 约翰斯霍普金斯大学 使用环磷酰胺治疗神经性自身免疫疾病
US20090137457A1 (en) 2007-10-02 2009-05-28 Concert Pharmaceuticals, Inc. Pyrimidinedione derivatives
JP2011500569A (ja) 2007-10-12 2011-01-06 マサチューセッツ インスティテュート オブ テクノロジー ワクチンナノテクノロジー
US20090105338A1 (en) 2007-10-18 2009-04-23 Protia, Llc Deuterium-enriched gabexate mesylate
WO2009051782A1 (en) 2007-10-18 2009-04-23 Concert Pharmaceuticals Inc. Deuterated etravirine
EP2217548A1 (en) 2007-10-26 2010-08-18 Concert Pharmaceuticals Inc. Deuterated darunavir
JP5450434B2 (ja) 2007-11-16 2014-03-26 アッヴィ・インコーポレイテッド 関節炎の治療方法
EP2219651A1 (en) 2007-12-06 2010-08-25 Abbott Laboratories Oral compositions of abt-263 for treating cancer
CN101970655B (zh) 2008-01-15 2014-03-05 Abbvie公司 改良哺乳动物表达载体及其用途
CN101220008B (zh) 2008-01-21 2011-04-27 中国科学院广州生物医药与健康研究院 化合物abt-263的合成方法
WO2009100176A2 (en) 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
CN101548960B (zh) 2008-04-01 2012-11-07 沈阳药科大学 高溶出度口服联苯双酯胶囊及其制备方法
US8168784B2 (en) 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
ME02640B (me) 2008-10-07 2017-06-20 Kudos Pharm Ltd Farmaceutske formulacije 514
US20100160322A1 (en) * 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8557983B2 (en) 2008-12-04 2013-10-15 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
UA108193C2 (uk) * 2008-12-04 2015-04-10 Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
US8563735B2 (en) * 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
EP3101019A1 (en) * 2008-12-05 2016-12-07 AbbVie Inc. Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US8586754B2 (en) 2008-12-05 2013-11-19 Abbvie Inc. BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
WO2010077740A2 (en) 2008-12-09 2010-07-08 Cytokine Pharmasciences, Inc. Novel antiviral compounds, compositions, and methods of use
US8959548B2 (en) * 2008-12-22 2015-02-17 Verizon Patent And Licensing Inc. Presenting advertisements with video program descriptions
US20120094963A1 (en) 2008-12-23 2012-04-19 of Queen Elizabeth near Dublin Targeting prodrugs and compositions for the treatment of gastrointestinal diseases
SG172393A1 (en) 2009-01-19 2011-07-28 Abbott Lab Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
BRPI1006116A2 (pt) * 2009-01-19 2018-03-13 Abbott Lab "agentes indutores da apoptose para o tratamento de câncer e doenças imunes e autoimunes".
US20100278921A1 (en) 2009-04-30 2010-11-04 Fischer Cristina M Solid oral formulation of abt-263
US20100280031A1 (en) 2009-04-30 2010-11-04 Paul David Lipid formulation of apoptosis promoter
US20100297194A1 (en) * 2009-04-30 2010-11-25 Nathaniel Catron Formulation for oral administration of apoptosis promoter
US8728516B2 (en) 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
US8362013B2 (en) 2009-04-30 2013-01-29 Abbvie Inc. Salt of ABT-263 and solid-state forms thereof
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
DK2435432T6 (da) * 2009-05-26 2023-12-18 Abbvie Ireland Unlimited Co Apoptose-inducerende midler til behandling af cancer og immune og autoimmune sygdomme
TWI532484B (zh) 2009-06-08 2016-05-11 艾伯維有限公司 包含凋亡促進劑之固態分散劑
TWI540132B (zh) 2009-06-08 2016-07-01 亞培公司 Ｂｃｌ-２族群抑制劑之口服醫藥劑型
EP2853531A3 (en) 2009-06-11 2015-08-12 AbbVie Bahamas Ltd. Antiviral compounds
AU2010260226A1 (en) 2009-06-18 2012-02-02 Abbvie Inc. Stable nanoparticulate drug suspension
WO2011034934A1 (en) 2009-09-20 2011-03-24 Abbott Laboratories Abt-263 crystalline forms and solvates for use in treating bcl-2 protein related diseases
CN101798292A (zh) 2010-03-29 2010-08-11 无锡好芳德药业有限公司 ABT-263衍生的新型Bcl-2蛋白抑制剂的制备
TWI520960B (zh) 2010-05-26 2016-02-11 艾伯維有限公司 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
EP2632436B1 (en) 2010-10-29 2018-08-29 Abbvie Inc. Solid dispersions containing an apoptosis-inducing agent
LT2643322T (lt) 2010-11-23 2018-01-10 Abbvie Inc. Apoptozę skatinančio agento druskos ir kristalinės formos
AU2011332000B2 (en) 2010-11-23 2016-07-07 Abbvie Ireland Unlimited Company Methods of treatment using selective Bcl-2 inhibitors
WO2013071138A1 (en) 2011-11-11 2013-05-16 Sio2 Medical Products, Inc. PASSIVATION, pH PROTECTIVE OR LUBRICITY COATING FOR PHARMACEUTICAL PACKAGE, COATING PROCESS AND APPARATUS

Also Published As

Publication number Publication date
MX345603B (es) 2017-02-03
RU2013124823A (ru) 2014-12-10
CA2813985C (en) 2019-01-15
DK2613769T3 (en) 2018-01-08
PT2613769T (pt) 2018-01-04
HRP20171884T1 (hr) 2018-01-12
RS56718B1 (sr) 2018-03-30
GT201300102A (es) 2014-05-20
ZA201302669B (en) 2014-10-29
NO2613769T3 (me) 2018-02-24
RU2633353C1 (ru) 2017-10-12
DOP2013000092A (es) 2013-09-30
JP2016147878A (ja) 2016-08-18
IL251877B (en) 2019-03-31
UA113500C2 (xx) 2017-02-10
MY189224A (en) 2022-01-31
TWI535699B (zh) 2016-06-01
ECSP13012647A (es) 2013-07-31
HK1243761A1 (en) 2018-07-20
SI2613769T1 (en) 2018-02-28
AR122475A2 (es) 2022-09-14
US20120108590A1 (en) 2012-05-03
CO6781472A2 (es) 2013-10-31
UY39192A (es) 2021-06-30
JP2013544804A (ja) 2013-12-19
TW201242946A (en) 2012-11-01
IL226215A0 (en) 2013-07-31
KR101957137B1 (ko) 2019-03-13
CY1119993T1 (el) 2018-12-12
TW201636324A (zh) 2016-10-16
EP4218731A2 (en) 2023-08-02
CA2813985A1 (en) 2012-09-13
EP2613769A1 (en) 2013-07-17
AR083656A1 (es) 2013-03-13
TWI648261B (zh) 2019-01-21
US11369599B2 (en) 2022-06-28
KR20140052921A (ko) 2014-05-07
RU2577859C2 (ru) 2016-03-20
SG189477A1 (en) 2013-05-31
BR112013010524A2 (pt) 2016-08-02
PE20140381A1 (es) 2014-04-21
CR20180289A (es) 2018-06-26
PH12013500686A1 (en) 2013-05-27
KR20180024025A (ko) 2018-03-07
IL226215A (en) 2017-05-29
JP5902187B2 (ja) 2016-04-13
UY33692A (es) 2012-04-30
KR101836820B1 (ko) 2018-03-09
CN108175749B (zh) 2021-09-10
HUE035169T2 (en) 2018-05-02
AU2011361704B2 (en) 2015-10-01
US20150148331A1 (en) 2015-05-28
JP6153638B2 (ja) 2017-06-28
CR20130224A (es) 2013-06-12
UY37326A (es) 2019-02-28
ECSP22086925A (es) 2023-01-31
LT2613769T (lt) 2018-02-12
EP4218731A3 (en) 2023-08-16
IL251877A0 (en) 2017-06-29
BR112013010524A8 (pt) 2018-02-06
ES2647583T3 (es) 2017-12-22
WO2012121758A1 (en) 2012-09-13
MX2013004843A (es) 2013-10-01
PL2613769T3 (pl) 2018-04-30
CL2013001120A1 (es) 2013-10-04
CN103282025A (zh) 2013-09-04
DOP2017000003A (es) 2017-04-16
ZA201401440B (en) 2015-06-24
SG2014015077A (en) 2014-04-28
CN103282025B (zh) 2018-01-02
PE20171242A1 (es) 2017-08-24
EP3219308A1 (en) 2017-09-20
AU2011361704A1 (en) 2013-05-02
CN108175749A (zh) 2018-06-19
EP2613769B1 (en) 2017-09-27
MX362113B (es) 2019-01-07
NZ608907A (en) 2015-05-29

Similar Documents

Publication Publication Date Title
ME02942B (me) Kruta disperzija dobivena ekstruzijom u rastaljenom stanju koja sadržava agens za induciranje apoptoze
JP2013544804A5 (me)
SI2982366T1 (en) A pharmaceutical dosage form for the oral administration of an inhibitor of the Bcl-2 family
RU2013124824A (ru) Твердые дисперсии, содержащие средства, вызывающие апоптоз
JP2013540823A5 (me)
RU2012101627A (ru) Стабильная суспензия лекарственного средства в виде наночастиц
BR112019018576A2 (pt) métodos de tratamento de doença de crohn e colite ulcerativa
JP2019529575A5 (me)
RU2020142739A (ru) Ингибиторы mdm2 и их комбинации
RU2011152628A (ru) Твердые дисперсии, содержащие способствующее апоптозу средство
RU2018103454A (ru) Соединения бензоксазепиноксазолидинонов и способы применения
SI2643322T1 (en) Salts and crystalline forms of an apoptosis-inducing agent
JP2018505193A5 (me)
JP2015232006A5 (me)
JP2008531714A (ja) 不安障害の治療用及び／又は予防用の医薬組成物
JP2002523447A (ja) ５−ｈｔ６アンタゴニストの使用
JP2013507415A5 (me)
RU2012118668A (ru) Комбинированная терапия с использованием агониста бета 3 адренергического рецептора и антимускаринового средства
JP2015536986A5 (me)
IL295803A (en) Hot melt extruded solid dispersions containing a bcl2 inhibitor
JP2023153796A (ja) 子宮内膜症、子宮筋腫、多嚢胞性卵巣症候群又は腺筋症を治療するための医薬製剤
EP3638232A1 (en) Tinostamustine for use in treating sarcoma
JP2015516988A5 (me)
CN107249327A (zh) 使用甲基纳曲酮减缓肿瘤进展
RU2017144574A (ru) Пероральная композиция целекоксиба для лечения боли